Scholar Rock Holding Corporation (SRRK)

5.96 -0.27 (-4.33%) At close: 04:00PM EDT

Scholar Rock Holding Corporation

301 Binney Street
3rd Floor
Cambridge, MA 02142
United States
857 259 3860
https://scholarrock.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Nagesh K. Mahanthappa MBA, Ph.D.	Interim CEO, Pres & Director	356.22k	N/A	1965
Mr. Edward H. Myles M.B.A., MBA	CFO, COO & Treasurer	615.87k	N/A	1972
Dr. Yung H. Chyung M.D.	Chief Medical Officer	613.61k	N/A	1976
Dr. Gregory John Carven Ph.D.	Chief Scientific Officer	N/A	N/A	1976
Ms. Catherine Hu	VP of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Junlin Ho J.D.	Gen. Counsel & Corp. Sec.	N/A	N/A	1979
Ms. Caryn Parlavecchio	Chief HR Officer	N/A	N/A	1972
Ms. Lisa Amaya Price	Sr. VP of HR	N/A	N/A	N/A
Dr. George G. Nomikos M.D., Ph.D.	Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area	N/A	N/A	N/A
Ms. Erin Moore	Sr. VP of Fin.	N/A	N/A	1975

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Scholar Rock Holding Corporation’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.